ATE356117T1 - Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität - Google Patents
Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivitätInfo
- Publication number
- ATE356117T1 ATE356117T1 AT03024911T AT03024911T ATE356117T1 AT E356117 T1 ATE356117 T1 AT E356117T1 AT 03024911 T AT03024911 T AT 03024911T AT 03024911 T AT03024911 T AT 03024911T AT E356117 T1 ATE356117 T1 AT E356117T1
- Authority
- AT
- Austria
- Prior art keywords
- oxy
- urea
- phenyl
- represent
- antitumor activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1485899 | 1999-01-22 | ||
JP2669199 | 1999-02-03 | ||
JP14249399 | 1999-05-21 | ||
JP25362499 | 1999-09-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE356117T1 true ATE356117T1 (de) | 2007-03-15 |
Family
ID=27456291
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03024911T ATE356117T1 (de) | 1999-01-22 | 2000-01-20 | Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität |
AT00900841T ATE253051T1 (de) | 1999-01-22 | 2000-01-20 | Chinolinderivate und chinazolinderivate |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00900841T ATE253051T1 (de) | 1999-01-22 | 2000-01-20 | Chinolinderivate und chinazolinderivate |
Country Status (20)
Country | Link |
---|---|
US (3) | US6797823B1 (de) |
EP (2) | EP1384712B1 (de) |
JP (2) | JP3519368B2 (de) |
KR (1) | KR100787254B1 (de) |
CN (1) | CN1183114C (de) |
AT (2) | ATE356117T1 (de) |
AU (1) | AU771504B2 (de) |
BR (1) | BR0007656A (de) |
CA (1) | CA2361057C (de) |
DE (2) | DE60033857T2 (de) |
ES (2) | ES2281591T3 (de) |
HK (1) | HK1043792A1 (de) |
HU (1) | HU230789B1 (de) |
IL (2) | IL144461A0 (de) |
NO (1) | NO321295B1 (de) |
NZ (1) | NZ513006A (de) |
PL (2) | PL206627B1 (de) |
TR (1) | TR200102090T2 (de) |
TW (1) | TWI229667B (de) |
WO (1) | WO2000043366A1 (de) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP1158985B1 (de) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | GAMMA CARBOXYARYLSUBSTITUIERTE DIPHENYLHARNSTOFFVERBINDUNGEN ALS p38 KINASEHEMMER |
WO2000043366A1 (fr) * | 1999-01-22 | 2000-07-27 | Kirin Beer Kabushiki Kaisha | Derives de quinoline et derives de quinazoline |
TWI281915B (en) * | 1999-12-24 | 2007-06-01 | Kirin Brewery | Quinoline and quinazoline derivatives and drugs containing the same |
DE60134679D1 (de) | 2000-10-20 | 2008-08-14 | Eisai R&D Man Co Ltd | Stickstoff enthaltende aromatische Heterozyklen |
GB0029015D0 (en) | 2000-11-28 | 2001-01-10 | Univ London | Medical device |
KR100879669B1 (ko) * | 2001-04-27 | 2009-01-21 | 기린 파마 가부시끼가이샤 | 아졸릴기를 갖는 퀴놀린 유도체 및 퀴나졸린 유도체 |
DE60233736D1 (de) | 2001-06-22 | 2009-10-29 | Kirin Pharma K K | Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung |
WO2003008388A1 (fr) * | 2001-07-19 | 2003-01-30 | Kirin Beer Kabushiki Kaisha | Cristal en i de n-?2-chloro-4-?(6,7-dimethoxy-4-quinazolinyl)oxy?phenyl?-n'-propyluree et methode de production du cristal |
EP1447405A4 (de) * | 2001-10-17 | 2005-01-12 | Kirin Brewery | Chinolin- oder chinazolinderivate, die die autophosphorylierung von rezeptoren für den fibroblastenwachstumsfaktor hemmen |
AU2003202094B2 (en) | 2002-02-01 | 2009-10-08 | Astrazeneca Ab | Quinazoline compounds |
US20030216396A1 (en) | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
PT1478358E (pt) | 2002-02-11 | 2013-09-11 | Bayer Healthcare Llc | Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal |
AU2003209118A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas as kinase inhibitors |
EP1535910A4 (de) * | 2002-05-01 | 2007-03-14 | Kirin Brewery | Chinolinderivate und chinazolinderivate, die die autophosphorilierung des macrophage colony stimulating factor receptors inhibieren |
US7202244B2 (en) | 2002-05-29 | 2007-04-10 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
AU2003249212C1 (en) | 2002-07-15 | 2011-10-27 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
EP1566379A4 (de) * | 2002-10-29 | 2005-11-09 | Kirin Brewery | CHINOLINDERIVATE UND CHINAZOLINDERIVATE ALS HEMMER DER Flt3-AUTOPHOSPHORYLIERUNG UND DIESE ENTHALTENDE MEDIZINISCHE ZUSAMMENSETZUNGEN |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
US7994159B2 (en) | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
JP2007511203A (ja) | 2003-05-20 | 2007-05-10 | バイエル、ファーマシューテイカルズ、コーポレイション | キナーゼ阻害活性を有するジアリール尿素 |
DE602004010407T2 (de) | 2003-07-23 | 2008-10-16 | Bayer Pharmaceuticals Corp., West Haven | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden |
ES2371383T3 (es) * | 2003-09-26 | 2011-12-30 | Exelixis, Inc. | N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer. |
AU2013204031B2 (en) * | 2003-09-26 | 2016-10-27 | Exelixis, Inc. | c-Met modulators and methods of use |
JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
WO2005051924A1 (ja) * | 2003-11-28 | 2005-06-09 | Mitsubishi Pharma Corporation | キナゾリン誘導体及びその製造方法 |
CN1890234A (zh) * | 2003-12-23 | 2007-01-03 | 辉瑞大药厂 | 新颖的喹啉衍生物 |
TW200530236A (en) | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
ATE517885T1 (de) | 2004-04-30 | 2011-08-15 | Bayer Healthcare Llc | Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs |
US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US8436006B2 (en) * | 2004-08-06 | 2013-05-07 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
US8426429B2 (en) | 2004-08-06 | 2013-04-23 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
US8383637B2 (en) * | 2004-08-06 | 2013-02-26 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
MX2007006230A (es) * | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
CN104688697A (zh) * | 2005-03-07 | 2015-06-10 | 拜尔健康护理有限责任公司 | 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 |
JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
TW200740820A (en) * | 2005-07-05 | 2007-11-01 | Takeda Pharmaceuticals Co | Fused heterocyclic derivatives and use thereof |
JP5066446B2 (ja) * | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を予測する方法 |
EP1925676A4 (de) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | Testverfahren für die wirkung eines vaskularisierungsinhibitors |
CA2620594C (en) * | 2005-09-01 | 2012-08-21 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition having improved disintegratability |
PT1942898E (pt) | 2005-09-14 | 2011-12-20 | Takeda Pharmaceutical | Inibidores da dipeptidilpeptidase para o tratamento da diabetes |
JP5122462B2 (ja) | 2005-09-16 | 2013-01-16 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
CN101316590B (zh) * | 2005-11-07 | 2011-08-03 | 卫材R&D管理有限公司 | 血管生成抑制剂和c-kit激酶抑制剂的组合使用 |
EP1964837A4 (de) * | 2005-11-22 | 2010-12-22 | Eisai R&D Man Co Ltd | Antitumormittel gegen multiples myelom |
US7868022B2 (en) * | 2006-02-06 | 2011-01-11 | Janssen Pharmaceutica Nv | 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE) |
US7932261B2 (en) * | 2006-02-06 | 2011-04-26 | Janssen Pharmaceutica Nv | Macrocycle derivatives useful as inhibitors of β-secretase (BACE) |
US7776882B2 (en) * | 2006-02-06 | 2010-08-17 | Baxter Ellen W | 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE) |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
ES2556173T3 (es) * | 2006-05-18 | 2016-01-13 | Eisai R&D Management Co., Ltd. | Agente antitumoral para un cáncer de tiroides |
EP2044939A1 (de) * | 2006-06-29 | 2009-04-08 | Eisai R&D Management Co., Ltd. | Therapeutisches mittel gegen leberfibrose |
JP5238697B2 (ja) | 2006-08-04 | 2013-07-17 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
WO2008020302A2 (en) * | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
US8865737B2 (en) * | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
WO2008044688A1 (fr) * | 2006-10-11 | 2008-04-17 | Daiichi Sankyo Company, Limited | Dérivé de l'urée |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
JPWO2008087736A1 (ja) * | 2007-01-19 | 2010-05-06 | 宇部興産株式会社 | アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法 |
EP2119707B1 (de) * | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Zusammensetzung zur behandlung von nicht differenzierten formen von magenkrebsen |
US8557853B2 (en) * | 2007-02-09 | 2013-10-15 | Allergan, Inc. | Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents |
CL2008001626A1 (es) | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
JP5270553B2 (ja) * | 2007-08-23 | 2013-08-21 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
BRPI0821227A2 (pt) * | 2007-12-19 | 2015-06-16 | Cancer Rec Tech Ltd | Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos |
CA2712367C (en) * | 2008-01-17 | 2016-01-19 | Bayer Schering Pharma Aktiengesellschaft | Sulphoximine-substituted quinazoline derivatives as immunomodulators, their preparation and use as medicaments |
NZ586831A (en) * | 2008-01-28 | 2012-02-24 | Janssen Pharmaceutica Nv | 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace) |
JP2011510993A (ja) * | 2008-01-29 | 2011-04-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | β−セクレターゼ(BACE)阻害剤として有用な2−アミノ−キノリン誘導体 |
AU2009210098B2 (en) * | 2008-01-29 | 2013-06-13 | Eisai R & D Management Co., Ltd. | Combined use of angiogenesis inhibitor and taxane |
DK2268623T3 (en) * | 2008-03-17 | 2015-06-29 | Ambit Biosciences Corp | QUINAZOLINE DERIVATIVES AS RAF CHINESE MODULATORS AND PROCEDURES FOR USE THEREOF |
US9206130B2 (en) * | 2008-04-16 | 2015-12-08 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinoline derivatives as AXL kinase inhibitors |
MX2011004018A (es) * | 2008-10-14 | 2011-06-24 | Ning Xi | Compuestos y metodos de uso. |
US8697874B2 (en) * | 2008-12-01 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
CN110818633A (zh) | 2009-01-16 | 2020-02-21 | 埃克塞里艾克西斯公司 | 一种苹果酸盐及其晶型 |
EP2408300B1 (de) * | 2009-03-21 | 2016-05-11 | Sunshine Lake Pharma Co., Ltd. | Aminoesterderivate, salze daraus und verfahren zu ihrer verwendung |
WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
CN101671301B (zh) * | 2009-05-05 | 2014-02-26 | 江苏省药物研究所有限公司 | 杂环取代的二苯脲类衍生物及其用途 |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
EP2594566A4 (de) | 2010-07-16 | 2014-10-01 | Kyowa Hakko Kirin Co Ltd | Mit stickstoff angereichertes aromatisches heterocyclisches ringderivat |
CA2826751C (en) | 2011-02-10 | 2021-05-18 | Exelixis, Inc. | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
CN102311395B (zh) * | 2011-07-05 | 2014-04-16 | 张爱华 | 喹唑啉环取代的二苯脲类衍生物及其用途 |
CN102432595B (zh) * | 2011-09-14 | 2013-09-25 | 湖南有色凯铂生物药业有限公司 | N-吲哚-1-酰胺类化合物及作为抗癌药物的应用 |
CN102408418A (zh) * | 2011-10-21 | 2012-04-11 | 武汉迈德森医药科技有限公司 | Tivozanib酸性盐及其制备方法和晶型 |
EP2780338B1 (de) | 2011-11-14 | 2016-11-09 | Ignyta, Inc. | Uracilderivate als axl- und c-met-kinaseinhibitoren |
CN102603718B (zh) * | 2012-02-08 | 2014-01-29 | 武汉凯斯瑞科技有限公司 | 西地尼布的合成方法 |
EP2626073A1 (de) | 2012-02-13 | 2013-08-14 | Harmonic Pharma | Verbindung zur Verwendung zur Prävention bzw. Behandlung einer neurogenerativen Erkrankung oder einer Erkrankung mit Phosphodiesterase (PDE4) -4-Aktivierung |
KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
US9695184B2 (en) | 2013-02-15 | 2017-07-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
AU2014216178B2 (en) * | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
KR102204279B1 (ko) | 2013-05-14 | 2021-01-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지 |
RS63559B1 (sr) | 2014-08-28 | 2022-10-31 | Eisai R&D Man Co Ltd | Derivat hinolina velike čistoće i postupak za njegovu proizvodnju |
PL3263106T3 (pl) | 2015-02-25 | 2024-04-02 | Eisai R&D Management Co., Ltd. | Sposób tłumienia goryczy pochodnej chinoliny |
AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
JP6740354B2 (ja) | 2015-10-05 | 2020-08-12 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | オートファジーの流れ及びホスホリパーゼd及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法 |
CN106496116A (zh) * | 2016-10-21 | 2017-03-15 | 沈阳药科大学 | 含双芳基脲结构的喹啉类化合物及其用途 |
WO2018102455A1 (en) | 2016-12-01 | 2018-06-07 | Ignyta, Inc. | Methods for the treatment of cancer |
CN108239067A (zh) * | 2016-12-27 | 2018-07-03 | 沈阳药科大学 | 喹唑啉酮类衍生物及其制备方法和用途 |
CN109824587A (zh) * | 2017-11-23 | 2019-05-31 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂xjf007及其中间体的制备方法 |
CN109553581B (zh) * | 2018-09-25 | 2022-01-25 | 广州六顺生物科技股份有限公司 | 取代脲化合物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
CN111303024B (zh) * | 2018-12-12 | 2023-03-28 | 安徽中科拓苒药物科学研究有限公司 | 一种喹啉结构的pan-KIT激酶抑制剂及其用途 |
JP2020100598A (ja) | 2018-12-25 | 2020-07-02 | 公益財団法人応用生化学研究所 | レンバチニブ誘導体、並びにそれを用いた医薬研究用組成物及び腫瘍治療剤 |
WO2021144360A1 (en) | 2020-01-17 | 2021-07-22 | F. Hoffmann-La Roche Ag | Small molecule csf-1r inhibitors in therapeutic and cosmetic uses |
CN113620873B (zh) * | 2020-05-07 | 2023-12-08 | 沈阳药科大学 | 含锌结合基以及喹啉骨架的化合物的制备方法和用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
JP2783722B2 (ja) * | 1991-07-12 | 1998-08-06 | 麒麟麦酒株式会社 | スピカマイシン誘導体およびそれを含む抗腫瘍剤 |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
CN1158599A (zh) * | 1994-09-20 | 1997-09-03 | 住友金属工业株式会社 | 介质陶瓷组成物及其制造方法 |
JP4009681B2 (ja) * | 1995-11-07 | 2007-11-21 | キリンファーマ株式会社 | 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物 |
JP4194678B2 (ja) * | 1997-11-28 | 2008-12-10 | キリンファーマ株式会社 | キノリン誘導体およびそれを含む医薬組成物 |
WO2000043366A1 (fr) * | 1999-01-22 | 2000-07-27 | Kirin Beer Kabushiki Kaisha | Derives de quinoline et derives de quinazoline |
TWI281915B (en) * | 1999-12-24 | 2007-06-01 | Kirin Brewery | Quinoline and quinazoline derivatives and drugs containing the same |
KR100879669B1 (ko) * | 2001-04-27 | 2009-01-21 | 기린 파마 가부시끼가이샤 | 아졸릴기를 갖는 퀴놀린 유도체 및 퀴나졸린 유도체 |
EP1447405A4 (de) * | 2001-10-17 | 2005-01-12 | Kirin Brewery | Chinolin- oder chinazolinderivate, die die autophosphorylierung von rezeptoren für den fibroblastenwachstumsfaktor hemmen |
EP1535910A4 (de) * | 2002-05-01 | 2007-03-14 | Kirin Brewery | Chinolinderivate und chinazolinderivate, die die autophosphorilierung des macrophage colony stimulating factor receptors inhibieren |
EP1559715B1 (de) * | 2002-10-21 | 2007-09-26 | Kirin Beer Kabushiki Kaisha | N-{2-chlor-4-[(6,7-dimethoxy-4-chinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)harnstoffsalzin kristalliner form |
EP1566379A4 (de) * | 2002-10-29 | 2005-11-09 | Kirin Brewery | CHINOLINDERIVATE UND CHINAZOLINDERIVATE ALS HEMMER DER Flt3-AUTOPHOSPHORYLIERUNG UND DIESE ENTHALTENDE MEDIZINISCHE ZUSAMMENSETZUNGEN |
US20040229676A1 (en) * | 2003-04-28 | 2004-11-18 | Gerald Duhamel | Method of playing a game of chance |
-
2000
- 2000-01-20 WO PCT/JP2000/000255 patent/WO2000043366A1/ja active IP Right Grant
- 2000-01-20 DE DE60033857T patent/DE60033857T2/de not_active Expired - Lifetime
- 2000-01-20 BR BR0007656-2A patent/BR0007656A/pt active Search and Examination
- 2000-01-20 ES ES03024911T patent/ES2281591T3/es not_active Expired - Lifetime
- 2000-01-20 EP EP03024911A patent/EP1384712B1/de not_active Expired - Lifetime
- 2000-01-20 DE DE60006216T patent/DE60006216T2/de not_active Expired - Lifetime
- 2000-01-20 US US09/889,858 patent/US6797823B1/en not_active Expired - Fee Related
- 2000-01-20 JP JP2000594782A patent/JP3519368B2/ja not_active Expired - Fee Related
- 2000-01-20 PL PL388667A patent/PL206627B1/pl not_active IP Right Cessation
- 2000-01-20 EP EP00900841A patent/EP1153920B1/de not_active Expired - Lifetime
- 2000-01-20 CA CA2361057A patent/CA2361057C/en not_active Expired - Fee Related
- 2000-01-20 AT AT03024911T patent/ATE356117T1/de not_active IP Right Cessation
- 2000-01-20 AT AT00900841T patent/ATE253051T1/de not_active IP Right Cessation
- 2000-01-20 NZ NZ513006A patent/NZ513006A/en not_active IP Right Cessation
- 2000-01-20 KR KR1020017009144A patent/KR100787254B1/ko not_active IP Right Cessation
- 2000-01-20 CN CNB008054282A patent/CN1183114C/zh not_active Expired - Fee Related
- 2000-01-20 ES ES00900841T patent/ES2208261T3/es not_active Expired - Lifetime
- 2000-01-20 IL IL14446100A patent/IL144461A0/xx active IP Right Grant
- 2000-01-20 TR TR2001/02090T patent/TR200102090T2/xx unknown
- 2000-01-20 HU HU0105133A patent/HU230789B1/hu unknown
- 2000-01-20 PL PL349036A patent/PL204856B1/pl not_active IP Right Cessation
- 2000-01-20 AU AU30748/00A patent/AU771504B2/en not_active Ceased
- 2000-01-21 TW TW089100998A patent/TWI229667B/zh not_active IP Right Cessation
-
2001
- 2001-05-29 NO NO20012617A patent/NO321295B1/no not_active IP Right Cessation
- 2001-07-19 IL IL144461A patent/IL144461A/en not_active IP Right Cessation
-
2002
- 2002-07-19 HK HK02105360A patent/HK1043792A1/xx not_active IP Right Cessation
-
2003
- 2003-05-06 JP JP2003128216A patent/JP2003286263A/ja not_active Withdrawn
-
2004
- 2004-05-10 US US10/842,009 patent/US7169789B2/en not_active Expired - Fee Related
-
2006
- 2006-09-26 US US11/526,739 patent/US20070027318A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE356117T1 (de) | Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität | |
BE2018C008I2 (de) | ||
ATE180468T1 (de) | Anthranilsäure derivate | |
DK0622361T3 (da) | Heterocykliske forbindelser som bradykininantagonister | |
DK0918776T3 (da) | Totalsyntese af antitumor acylfulvener | |
AU2492500A (en) | Aspartic protease inhibitors, compositions, and associated therapeutic methods | |
ATE232528T1 (de) | Pyrimidinylpyrazolderivate | |
DK1847534T3 (da) | Thiadiazolin-derivater til behandling af kræft | |
IL160874A0 (en) | 4-imidazolin-2-one derivatives | |
DE60016384D1 (de) | Chondrogonese promotoren und indolin-2-on derivate | |
DE69702775D1 (de) | Chinolinonderivate und diese enthaltende antiallergische Zusammensetzungen | |
ES2155655T3 (es) | Compuestos de benzotiofeno, usos y formulaciones de los mismos. | |
IL159792A0 (en) | Variolin derivatives and pharmaceutical compositions containing the same | |
DE69828087D1 (de) | Aminderivate | |
EP1251129A4 (de) | Pyrimidinderivate mit antitumor-wirkung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |